From StructContinue beyond “Veeva’s Supplier Is Also Building a Rival”Back to the brief ↗Feed / ALKS

Alkermes plc

ALKS

Healthcare · 48.37 -2.5% today

You’ve read what changed. Here’s whether the market is confirming it.

SpreadingMarket checked 6 Aug, 15:55 GMT-4

Jodie situation report

Alkermes plc's move is spreading beyond its market group.

The latest filing evidence is available. 10 of 12 group members are active now; 2 filing-linked outsiders are moving with the group, and 0 of 17 directly disclosed connections are confirming.

What changed
  • Revenue increased 28.2% versus the comparable filing period.
  • Operating income moved from a profit to a loss in the comparable period.
Company-2.5% todayVolume comparison unavailable
Market group10 of 12 activeBiotechnology Therapeutics · active
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Participation remains broad in the next market snapshot.
  • PFE remains aligned with the group in the next market snapshot.
  • Interest expense increased due to financing costs related to the Bridge Credit Agreement through the Avadel closing and interest on the Facilities.

Invalidation: This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.

Watch this read

Latest filing assessment · baseline

The latest filing shows material pressure

10-Q filed 2026-05-05 against the comparable filing from 2025-05-01.

cautious
OperationsmixedEvidence score 0
liquiditycautiousEvidence score -2
valuationmixed

What improved

  • Revenue increased 28.2% versus the comparable filing period.

What weakened

  • Operating income moved from a profit to a loss in the comparable period.
  • Operating cash flow remained negative at -165.7M.
  • Cash declined 48.3M versus the comparable period.

Filing receipts

“Financing Activities Cash flows provided by financing activities for the three months ended March 31, 2026 were primarily due to $1,511.6 million in net proceeds from borrowings under the Facilities in connection with the Avadel Acquisition and $15.7 million of cash that we received upon exercises of employee stock options, partially offset by $27.7 million (exclusive of any fees, commissions or other related expenses) used to repurchase our ordinary shares under the Repurchase Program and $23.4 million of employee taxes paid related to the net share settlement of equity awards.”

“The change in net loss of $88.9 million was primarily due to an increase of $148.5 million in total operating expenses, due to increases in cost of goods manufactured and sold, R&D expenses, selling, general and administrative expenses and amortization of acquired intangible assets, and due to an increase of $20.9 million of interest expense.”

“Cash flows provided by financing activities for the three months ended March 31, 2025 were primarily due to $29.5 million of cash that we received upon exercises of employee stock options, partially offset by $28.8 million of employee taxes paid related to the net share settlement of equity awards.”

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.